China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%

MT Newswires Live

2025/08/11

China's National Medical Products Administration accepted Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.

During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.

The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558990639"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558990639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558990639?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 13:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558990639","market":"hk","top_or_hot":-1,"title":"China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration accepted <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a>' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.</p><p>During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.</p><p>The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-11 13:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration accepted <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a>' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.</p><p>During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.</p><p>The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558990639","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558990639","pubTimestamp":1754890349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration accepted Shanghai Junshi Biosciences'  application to market the drug toripalimab in combination with another drug developed by RemeGen , according to a Hong Kong bourse filing on Saturday.During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","688331":"荣昌生物","BK1583":"高瓴概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","01877":"君实生物","09995":"荣昌生物","BK1515":"抗疫概念","BK1161":"生物科技","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"中国药品监督管理局受理君实将特瑞普利单抗与瑞美健药物联用的申请；君实股价下跌1%，RemeGen下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"688331":0.9,"01877":0.9,"09995":0.9},"content_text":"China's National Medical Products Administration accepted Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}